StockData
Becton Dickinson & Co logo

Becton Dickinson & Co

BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3018% above fair value
$215.42−1.05 (-0.49%)

Close on Nov 17, 2026Market cap $58.68BP/E 65.1Yield 1.93%

Becton Dickinson Target/Actual Enrollment in Newly Started Studies by Year

Target/Actual Enrollment in Newly Started Studies (participants)

Periods

Becton Dickinson Target/Actual Enrollment in Newly Started Studies: 1,741 in FY2026, down 16.1% from a year earlier.

Latest, FY2026
1,741
Period ended Sep 30, 2026 (CY2026)
Change on a year earlier
-16.1%
2,074 in FY2025
History
12 years
Since FY2015
Sources
1
NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard

Where the FY2026 figure comes from

Source: NIH ClinicalTrials.gov Registry — Becton Dickinson & C.R. Bard ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Becton Dickinson Target/Actual Enrollment in Newly Started Studies, annual FY2015–FY2026 [Data set]. Compiled from Becton Dickinson SEC filings and investor materials. https://stockdatahq.com/stocks/bdx/kpis/ext-ct-enroll

See every metric in the Becton Dickinson KPI table. Data updated Nov 7, 2026.

See a number that looks wrong?